Gavin Davidson, CVMD Analyst, GlobalData, examines how MDMA is used to treat patients...
doc.ai’s digital health trial to improve Epilepsy treatment
Healthcare startup doc.ai has launched the Epilepsy Digital Health Trial to improve treatment options for the condition and to test how artificial intelligence (AI) can help create a predictive and accurate treatment for curing diseases.
New trial announced to assess cannabidiol in Parkinson’s patients
A new Phase II clinical trial will be conducted to assess cannabidiol (CBD) for the treatment of hallucinations and delusions associated with Parkinson’s disease.
Alder commences ALD1910 dosing in Phase I migraine trial
Alder BioPharmaceuticals has dosed the first participant in a Phase I clinical trial being conducted to assess its investigational monoclonal antibody (mAb) ALD1910 for the prevention of migraine.
Oryzon reveals positive data from anti-aggression drug vafidemstat
Oryzon Genomics has announced new aggregated positive human efficacy data on its central nervous system (CNS) epigenetic drug vafidemstat from three different cohorts of psychiatric patients in a Phase II REIMAGINE trial.
Biogen explores new options for Spinraza as competitive threats escalate
In 2016, Biogen's Spinraza became the first therapy to receive marketing authorisation for SMA, a rare neurodegenerative disease that primarily affects children.
NIMH funds clinical research to improve Schizophrenia treatment
The National Institutes of Mental Health (NIMH) has granted $7.3m to researchers at the Feinstein Institutes for Medical Research to support their efforts to provide improved treatment for schizophrenia.
Trial finds depression drug sertraline reduces anxiety first
A new clinical trial led by University College London (UCL) has found that common antidepressant sertraline causes a decrease in anxiety weeks before relieving depressive symptoms.